Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice
In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component c...
Saved in:
Published in | International immunopharmacology Vol. 55; pp. 306 - 311 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.02.2018
Elsevier BV |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In a previous study, we constructed a MHSP65-TCL anti-lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti-lung cancer effect through specific and nonspecific anti-tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component can be eliminated from TCL, the anti-tumor immunity of MHSP65-TCL constructed with TCL should be improved. In the present study, we knocked down FasL from Lewis lung carcinoma cells and prepared MHSP65-(FasL-/TCL) with this cell line's TCL. After further investigation, MHSP65-(FasL-/TCL) exhibited a better ability to reduce splenocytes apoptosis, promote its activation and secretion of secretingTNF-β, IL-2 compared with MHSP65-(FasL+/TCL). Accordingly, specific and nonspecific antitumor immunity induced by MHSP65-(FasL-/TCL) is stronger than that of MHSP65-(FasL+/TCL). In vivo, MHSP65-(FasL-/TCL) immunization can prolong survival of Lewis lung carcinoma bearing mice. Thus, we report that the anti-lung cancer effect of MHSP65-TCL can be improved by removal of FasL from the TCL. It provides a new route to construct MHSP65-TCL and other antitumor vaccines based on TCL.
•Constructed a MHSP65-(FasL-/TCL) anti-lung cancer vaccine with the TCL removed FasL (FasL-/TCL).•MHSP65-(FasL-/TCL) can induce stronger nonspecific and specific anti-lung cancer immunity than MHSP65-(FasL+/TCL).•MHSP65-(FasL-/TCL) immunization can prolong survival of tumor bearing mice compared with that of MHSP65-(FasL+/TCL).•Theoretically, the method eliminated FasL from TCL can be applied in all the immunotherapy based on TCL. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1567-5769 1878-1705 |
DOI: | 10.1016/j.intimp.2017.12.029 |